TY - JOUR
T1 - Risk assessment for vitamin D
AU - Hathcock, John N.
AU - Shao, Andrew
AU - Vieth, Reinhold
AU - Heaney, Robert
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The objective of this review was to apply the risk assessment methodology used by the Food and Nutrition Board (FNB) to derive a revised safe Tolerable Upper Intake Level (UL) for vitamin D. New data continue to emerge regarding the health benefits of vitamin D beyond its role in bone. The intakes associated with those benefits suggest a need for levels of supplementation, food fortification, or both that are higher than current levels. A prevailing concern exists, however, regarding the potential for toxicity related to excessive vitaminDintakes. The UL established by the FNB for vitaminD(50 μg, or 2000 IU) is not based on current evidence and is viewed by many as being too restrictive, thus curtailing research, commercial development, and optimization of nutritional policy. Human clinical trial data published subsequent to the establishment of the FNB vitamin D UL published in 1997 support a significantly higher UL. We present a risk assessment based on relevant, well-designed human clinical trials of vitamin D. Collectively, the absence of toxicity in trials conducted in healthy adults that used vitamin D dose ≥250 μg/d (10 000 IU vitamin D3) supports the confident selection of this value as the UL.
AB - The objective of this review was to apply the risk assessment methodology used by the Food and Nutrition Board (FNB) to derive a revised safe Tolerable Upper Intake Level (UL) for vitamin D. New data continue to emerge regarding the health benefits of vitamin D beyond its role in bone. The intakes associated with those benefits suggest a need for levels of supplementation, food fortification, or both that are higher than current levels. A prevailing concern exists, however, regarding the potential for toxicity related to excessive vitaminDintakes. The UL established by the FNB for vitaminD(50 μg, or 2000 IU) is not based on current evidence and is viewed by many as being too restrictive, thus curtailing research, commercial development, and optimization of nutritional policy. Human clinical trial data published subsequent to the establishment of the FNB vitamin D UL published in 1997 support a significantly higher UL. We present a risk assessment based on relevant, well-designed human clinical trials of vitamin D. Collectively, the absence of toxicity in trials conducted in healthy adults that used vitamin D dose ≥250 μg/d (10 000 IU vitamin D3) supports the confident selection of this value as the UL.
UR - http://www.scopus.com/inward/record.url?scp=33846047531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846047531&partnerID=8YFLogxK
U2 - 10.1093/ajcn/85.1.6
DO - 10.1093/ajcn/85.1.6
M3 - Review article
C2 - 17209171
AN - SCOPUS:33846047531
SN - 0002-9165
VL - 85
SP - 6
EP - 18
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
IS - 1
ER -